Clinical Trial

Genflow to Attend Healthcare Conference

Genflow to Attend the 44th Annual J.P. Morgan Healthcare Conference LONDON, UK / ACCESS Newswire / December 11, 2025 /…

2 weeks ago

ECOG-ACRIN and Caris Life Sciences unveil first findings from a multi-year collaboration to advance AI-powered multimodal tools for breast cancer recurrence risk stratification

New AI models integrating imaging, clinical, and molecular data from the TAILORx tissue biorepository show stronger prognostic performance than current…

2 weeks ago

Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000

Calgary, Alberta--(Newsfile Corp. - December 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"),…

2 weeks ago

Sentynl Selects myTomorrows to Lead Managed Access Program

Reinforcing its commitment to rare disease treatment access, Sentynl is transitioning its program to myTomorrows patient-centric platform. AMSTERDAM, Dec. 10, 2025…

2 weeks ago

Spectrum Science Unifies Portfolio Companies Under Single Brand, Reinforcing Power of Integrated Strategic Platform

Connected Brand Identity Simplifies Access to Innovative, Agile Solutions that Drive Momentum for Companies in the Health and Life Science…

2 weeks ago

Veritiv Expands Its TempSafe® Portfolio With the Industry’s First Curbside-Recyclable Pallet Shipper for Biopharmaceutical Cold Chain

ATLANTA, Dec. 10, 2025 /PRNewswire/ -- Veritiv Operating Company, a leader in specialty packaging distribution, facility solutions and print products and…

2 weeks ago

Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer

Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant…

2 weeks ago

Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer

Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant…

2 weeks ago